We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

OPTiMASK: Comparison of Pre-oxygenation With Standard Face Mask Combined With High Flow Nasal Oxygen With Pre-oxygenation With Standard Face Mask Alone

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05495841
Recruitment Status : Recruiting
First Posted : August 10, 2022
Last Update Posted : December 12, 2022
Sponsor:
Information provided by (Responsible Party):
Daniel Talmor, Beth Israel Deaconess Medical Center

Tracking Information
First Submitted Date August 4, 2022
First Posted Date August 10, 2022
Last Update Posted Date December 12, 2022
Actual Study Start Date August 18, 2022
Estimated Primary Completion Date December 30, 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: August 9, 2022)
Lowest EtO2 value [ Time Frame: start of intubation to 2 minutes after ]
Lowest EtO2 value within the two minutes following tracheal intubation
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures
 (submitted: August 9, 2022)
  • SpO2 at the start and at the end of the procedure [ Time Frame: start of intubation to 4 minutes after ]
    SpO2 at the start and at the end of the procedure and EtO2 each minute during the four minutes of pre-oxygenation
  • Tolerance of the device [ Time Frame: entirety of procedure ]
    Tolerance of the device (discomfort considered if the patient asks for reduction of the gas flow of HFNC: Yes or No
  • Lowest SpO2 [ Time Frame: start of intubation to 2 minutes after ]
    Lowest SpO2 during intubation and within 2 min after intubation
  • Highest level of EtCO2 [ Time Frame: start of intubation to 2 minutes after ]
    Highest level of EtCO2 within 2 min following intubation
  • Rate of oxygen desaturation [ Time Frame: entirety of procedure ]
    Rate of oxygen desaturation below 95% during the procedure
  • Number of laryngoscopy attempts [ Time Frame: before surgical procedure ]
    Number of laryngoscopy attempts before successful tracheal intubation
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title OPTiMASK: Comparison of Pre-oxygenation With Standard Face Mask Combined With High Flow Nasal Oxygen With Pre-oxygenation With Standard Face Mask Alone
Official Title OPTiMASK: Comparison of Pre-oxygenation With Standard Face Mask Combined With High Flow Nasal Oxygen With Pre-oxygenation With Standard Face Mask Alone
Brief Summary This is an observational, prospective study of patients undergoing a surgical procedure. Three parallel studies are taking place with collaborators in other countries. This study aims to bring novel insights regarding the benefits of pre-oxygenation combining standard oxygen facemask with high-flow nasal oxygen (HFNO), as opposed to standard oxygen facemask alone by assessing end-tidal oxygen (ETO2) levels after intubation.
Detailed Description

This is an observational, prospective study of patients undergoing a surgical procedure. A total of 80 patients will be enrolled at BIDMC. Patients meeting inclusion criteria with no exclusions will be approached for consent. 40 patients receiving the pre-oxygenation face mask alone method during clinical routine and 40 patients using the pre-oxygenation combined facemask + HFNO technique as part of routine clinical care will be studied. No randomization will be employed. Choice of pre-oxygenation approach is at the discretion of the clinician. Patients will be enrolled as a convenience sample, such that the first 40 patients will be those with face mask alone, and the second 40 will be patients with face mask + HFNO. Research assistants will discuss the pre-oxygenation plan with the anesthesiologist as part of the screening process. Data will be collected including EtO2 levels during two minutes following intubation.

Methodology

  1. Face mask alone: As per clinical standard, the standard oxygen facemask will be tightly applied on the face of the patient at 100% FiO2 for 3 to 4 minutes. In case of suspected full stomach, it is recommended to perform a rapid sequence induction and the patient does not receive bag-mask ventilation during the apnea period (45-60s). In the other case, a standard pre-oxygenation will be performed (see figure 1: experimental design of the study).
  2. Face mask + Nasal cannula: As to clinical standards, the standard oxygen facemask will be tightly applied on the face of the patient at 100% FiO2 for 3 to 4 minutes and HFNO at 100% with a flow at 40 L/minutes during the pre-oxygenation (the flow can be decreased to less than 40 L/minutes if no tolerance by the patient). Then, after a general anesthesia induction and/or a rapid sequence induction is performed, the patient receives HFNO at 100% FiO2 and the flow of HFNO is increased to up to 80 L/minutes (which corresponds to a close delivered FiO2 at 80%) during the apnea period (1 to 2 min) until correct position of the endotracheal tube is confirmed with capnography.

Assessments The study does not require any research procedures other than passive data collection. For this study, EtO2 levels will be recorded at more frequent intervals than what is entered in the anesthesia record. Therefore, study staff will collect these data from the anesthesia machine in the operating room, where values are displayed on a breath-by-breath basis

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population This study accepts patients undergoing a surgical procedure. Patients would be considered for eligibility regardless of race, ethnicity or gender.
Condition Surgery
Intervention Device: Pre-oxygenation
Process of administrating oxygen prior to intubation
Study Groups/Cohorts
  • Face Mask Alone
    40 patients receiving the pre-oxygenation face mask alone method during clinical routine will be studied. As per clinical standard, the standard oxygen facemask will be tightly applied on the face of the patient at 100% FiO2 for 3 to 4 minutes. In case of suspected full stomach, it is recommended to perform a rapid sequence induction and the patient does not receive bag-mask ventilation during the apnea period (45-60s). In the other case, a standard pre-oxygenation will be performed (see figure 1: experimental design of the study).
    Intervention: Device: Pre-oxygenation
  • Face Mask and Nasal Cannula
    40 patients using the pre-oxygenation combined facemask + HFNO technique as part of routine clinical care will be studied. As to clinical standards, the standard oxygen facemask will be tightly applied on the face of the patient at 100% FiO2 for 3 to 4 minutes and HFNO at 100% with a flow at 40 L/minutes during the pre-oxygenation (the flow can be decreased to less than 40 L/minutes if no tolerance by the patient). Then, after a general anesthesia induction and/or a rapid sequence induction is performed, the patient receives HFNO at 100% FiO2 and the flow of HFNO is increased to up to 80 L/minutes (which corresponds to a close delivered FiO2 at 80%) during the apnea period (1 to 2 min) until correct position of the endotracheal tube is confirmed with capnography.
    Intervention: Device: Pre-oxygenation
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: August 9, 2022)
80
Original Estimated Enrollment Same as current
Estimated Study Completion Date December 30, 2025
Estimated Primary Completion Date December 30, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • 18 years and older
  • All consecutive patients for scheduled or non-scheduled surgery with or without indication of rapid sequence induction (full-stomach)
  • Undergoing general anesthesia with orotracheal intubation

Exclusion Criteria:

  • Age < 18 years
  • Hemodynamic instability
  • Intubation without laryngoscopy (i.e., fiberoptic intubation for anticipated "cannot ventilate situation" or mouth opening < 2 cm), facial surgery
  • Adults subject to legal protection
  • Pregnancy (due to higher risk of oxygen desaturation and aspiration)
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts
Contact: Ryan Mathura, MPH 617-632-8067 rmathura@bidmc.harvard.edu
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT05495841
Other Study ID Numbers 2022P000396
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: No
Plan Description: This study will conduct anonymous data collection in order to ensure the anonymity of each person participating in the study. No information allowing the identification of persons will be communicated to third parties.
Current Responsible Party Daniel Talmor, Beth Israel Deaconess Medical Center
Original Responsible Party Same as current
Current Study Sponsor Beth Israel Deaconess Medical Center
Original Study Sponsor Same as current
Collaborators Not Provided
Investigators
Principal Investigator: Daniel S Talmor, MD Beth Israel Deaconess Medical Center
PRS Account Beth Israel Deaconess Medical Center
Verification Date December 2022